Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 36

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 36
---
 deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation
paid to Wainwright will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification
and contribution to Wainwright against certain liabilities, including liabilities under the Securities Act.

The offering of our common shares pursuant
to this prospectus supplement will terminate upon the earlier of (a) the sale of the shares pursuant to this prospectus supplement and
the accompanying prospectus having, or (b) termination of the Sales Agreement by us or the Sales Agent as permitted therein.

| S-21 |

To the extent required by Regulation
M, Wainwright will not engage in any market making activities involving our common shares while the offering is ongoing under this prospectus
supplement.

From time to time, Wainwright and its
affiliates have and may provide in the future various advisory, investment and commercial banking and other services to us and our affiliates
in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions. In addition,
in the ordinary course of its various business activities, Wainwright and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans)
for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or
instruments of ours or our affiliates. Wainwright or its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. Except as disclosed in this prospectus supplement, we have no present
arrangements with Wainwright for any further services.

This summary of the material provisions
of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement is filed
with the SEC on a Current Report on Form 8-K and incorporated by reference into this prospectus supplement.

This prospectus supplement and accompanying
prospectus in electronic format may be made available on a website maintained by Wainwright and Wainwright may distribute this prospectus
electronically.

Our transfer agent and registrar for
our common shares is Computershare Investor Services Inc. located at 100 University Avenue, 8th Floor,